Ozempic Hype Forces Employer Calls on Obesity Coverage
Employers are facing a big dilemma: How do they pay for the new highly effective and popular obesity medications without breaking the bank?
Read MoreEmployers are facing a big dilemma: How do they pay for the new highly effective and popular obesity medications without breaking the bank?
Read MoreA recent JAMA study sheds light on how the manufacturers of a class of popular weight-loss drugs have avoided competition from more affordable generics.
Read MoreWe explain how Medicare’s historic price negotiations with drugmakers will work, and the impact they could have.
Read MoreRecent analyses in JAMA and by the Kaiser Family Foundation raise questions about whether Medicare and its beneficiaries can afford a new wave of Alzheimer’s treatments.
Read MoreTwo recent studies show the impact of an ongoing, COVID-era rule that let doctors treat opioid addiction entirely remotely.
Read MoreMedicare director Meena Seshamani discusses her team’s sprint to put historic drug price reforms into action.
Read MoreIn 2023 states will pursue new abortion laws, restart Medicaid eligibility checks and Medicare begins to flex its new power to negotiate drug prices.
Read MoreMore than $50 billion in opioid settlement dollars from drugmakers, distributors and pharmacies are starting to flow to state and local governments.
Read More